Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

NCT06081894 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT06081894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06081894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Cytokinetics
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 31, 2023
Completion date
November 30, 2026
Enrollment
500 (estimated)
Sites
180

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic non-obstructive hypertrophic cardiomyopathy